This company is no longer activeThe company may no longer be operating, as it may be out of business. Find out why through their latest events.See Latest EventsBerGenBio (BRRG.F) 주식 개요As of October 29, 2025, BerGenBio ASA was acquired by Oncoinvent ASA, in a reverse merger transaction. 자세히 보기BRRG.F 펀더멘털 분석스노우플레이크 점수가치 평가0/6미래 성장0/6과거 실적0/6재무 건전성4/6배당0/6위험 분석향후 3년 동안 수익이 연평균 20.2% 감소할 것으로 예상됩니다.수익이 USD$1m 미만입니다(NOK354K)지난 1년 동안 주주가 크게 희석되었습니다.주식은 유동성이 매우 낮습니다+ 위험 3건 추가모든 위험 점검 보기BRRG.F Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair ValueUS$Current PriceUS$0.02513.8k% 고평가 내재 할인율Est. Revenue$PastFuture-386m9m2016201920222025202620282031Revenue NOK 5.3mEarnings NOK 961.6kAdvancedSet Fair ValueView all narrativesBerGenBio ASA 경쟁사ABVC BioPharmaSymbol: NasdaqCM:ABVCMarket cap: US$27.2mAligos TherapeuticsSymbol: NasdaqCM:ALGSMarket cap: US$35.3mMedicus PharmaSymbol: NasdaqCM:MDCXMarket cap: US$15.8mOS TherapiesSymbol: NYSEAM:OSTXMarket cap: US$76.5m가격 이력 및 성과BerGenBio 주가의 최고가, 최저가 및 변동 요약과거 주가현재 주가NOK 0.02552주 최고가NOK 0.02552주 최저가NOK 0.025베타1.421개월 변동0%3개월 변동n/a1년 변동n/a3년 변동-99.36%5년 변동n/aIPO 이후 변동-99.37%최근 뉴스 및 업데이트공시 • Oct 31Oncoinvent ASA (OB:ONCIN) completed the acquisition of BerGenBio ASA (OB:BGBIO) from Hadean Capital I AS and Hventures Capital I AB, managed by Hadean Ventures and others in a reverse merger transaction.Oncoinvent ASA (OB:ONCIN) agreed to acquire BerGenBio ASA (OB:BGBIO) from Hadean Capital I AS and Hventures Capital I AB, managed by Hadean Ventures and others in a reverse merger transaction for approximately NOK 220 million on June 30, 2025. As part of the deal, NOK 217.47 million shall be paid towards the common equity of BerGenBio ASA. The exchange ratio for the merger is 1.20268049. This is an all-share transaction, the BerGenBio shareholders will receive 25% and Oncoinvent 75% of this merged company. And technically, it's BerGenBio will be the surviving entity, but it will be then we name Oncoinvent. So Oncoinvent will be the name going forward when this is all fully completed. Øystein Soug and Tore Kvam will be appointed as the CEO and CFO of the merged entity respectively. The transaction is subject to approval by regulatory board / committee, approval of offer by acquirer shareholders, approval of offer by target shareholders and approval/consents of lenders/creditors. The expected completion of the transaction is around mid-September 2025. As of September 17, 2025 the Merger will be completed on or about 29 October 2025. ABG Sundal Collier ASA acted as financial advisor for Oncoinvent ASA. Advokatfirmaet Schjødt As acted as legal advisor for Oncoinvent ASA. DNB Carnegie acted as financial advisor for BerGenBio ASA. Advokatfirmaet Thommessen AS acted as legal advisor for BerGenBio ASA. Oncoinvent ASA (OB:ONCIN) completed the acquisition of BerGenBio ASA (OB:BGBIO) from Hadean Capital I AS and Hventures Capital I AB, managed by Hadean Ventures and others in a reverse merger transaction on October 29, 2025.공시 • Oct 30BerGenBio ASA, Annual General Meeting, May 20, 2026BerGenBio ASA, Annual General Meeting, May 20, 2026.공시 • Jul 01BerGenBio ASA (OB:BGBIO) agreed to acquire Oncoinvent ASA (OB:ONCIN) from Hadean Capital I AS and Hventures Capital I AB, managed by Hadean Ventures and others for NOK 164.2 million.BerGenBio ASA (OB:BGBIO) agreed to acquire Oncoinvent ASA (OB:ONCIN) from Hadean Capital I AS and Hventures Capital I AB, managed by Hadean Ventures and others for NOK 164.2 million on June 30, 2025. Aspart of the consideration, BerGenBio ASA will issue 117.6 million shares to Oncoinvent ASA. The exchange ratio for the merger is 1.20268049. The merged company is expected to be renamed Oncoinvent. Øystein Soug and Tore Kvam will be appointed as the CEO and CFO of the merged entity respectively. The transaction is subject to approval by regulatory board / committee, approval of offer by acquirer shareholders, approval of offer by target shareholders and approval/consents of lenders/creditors. The expected completion of the transaction is around mid-September 2025. ABG Sundal Collier ASA acted as financial advisor for Oncoinvent ASA. Advokatfirmaet Schjødt As acted as legal advisor for Oncoinvent ASA. DNB Carnegie acted as financial advisor for BerGenBio ASA. Advokatfirmaet Thommessen AS acted as legal advisor for BerGenBio ASA.공시 • Mar 26BerGenBio ASA Announces Nature Communications Publication of BGBC003 Ph2 Data in Relapsed/Refractory Acute Myeloid Leukemia PatientsBerGenBio ASA announced the publication of a peer-reviewed article entitled "Bemcentinib as Monotherapy and in Combination with Low-Dose Cytarabine in Acute Myeloid Leukemia Patients Unfit for Intensive Chemotherapy" in the journal Nature Communications. The article highlights results in 36 patients treated with a combination of BerGenBio's selective oral AXL inhibitor bemcentinib in combination with low-dose cytarabine (LDAC) chemotherapy. Overall, patients who received the combination had an overall survival of 7.8 months, substantially longer than that expected in this difficult-to-treat patient population.공시 • Feb 26BerGenBio ASA Announces Discinuation of 1L STK11M NSCLC Study and Exploration of Strategic AlternativesBerGenBio ASA announced its decision to close its BGBC016 study of bemcentinib in combination with standard of care therapy in first line (1L) non-squamous Non-Small Cell Lung Cancer (NSCLC) patients with a mutation in the STK11 gene (STK11m). In 2024, the company announced the completion of enrollment in the Ph1b portion of the study which demonstrated acceptable safety in 1L NSCLC patients regardless of STK11 mutational status, as evaluated by an independent Data Safety Monitoring Board (DSMB). Early encouraging data were seen in three STK11m patients, including one patient who experienced a complete response and who remains in response and on treatment after nearly two years. The company, in agreement with the independent DSMB, determined that these initial results warranted the continuation of the study into the Ph2a portion. In March 2024, the company initiated the Ph2a portion of the study designed to recruit 40 evaluable 1L STK11m NSCLC patients. The primary endpoint for the Ph2a was overall response rate (ORR). To determine the feasibility of obtaining near-term funding, the company performed a preliminary analysis of the responses in the 10 efficacy evaluable STK11m patients. While there was 1 response in the Ph1b the company did not observe additional responses in the Ph2a patients. Consequently, the company has decided to discontinue the BGBC016 study. The Board of Directors has now initiated an exploration of strategic alternatives. As part of this process, the board will consider a range of options for the company including, among other things, a potential sale, merger, or other strategic transaction. There can be no assurance that this exploration process will result in any transaction.공시 • Jan 07Bergenbio Asa Announces First Patient Enters into Advanced Adenocarcinoma Lung Cancer TrialBerGenBio ASA announced that the first patient has been included in a clinical trial sponsored by the Mays Cancer Center at The University of Texas Health Science Center at San Antonio (UT Health San Antonio). The study is led by Josephine A. Taverna, MD, a thoracic oncologist at the Mays Cancer Center and Associate Professor in the Division of Hematology and Oncology at UT Health San Antonio. The trial is designed to study BerGenBio's bemcentinib in combination with pacritinib, which is a JAK2 inhibitor indicated for treatment of the bone marrow disorder myelofibrosis in patients with platelet counts below 50 x 109/L. It works by blocking certain growth factors and cytokines. Pacritinib is marketed in the United States as VONJO and owned by Swedish Orphan Biovitrum AB (Sobi), a specialized international biopharmaceutical company. Bemcentinib is a first-in-class, selective, oral once-a-day inhibitor of AXL receptor tyrosine kinase, a promising therapeutic target for serious diseases. The study will include patients with lung adenocarcinoma, the most common type of lung cancer in the United States, accounting for approximately 40% of all lung cancers. The study is funded by a grant from the National Cancer Institute (NCI) of the National Institutes of Health (NIH).더 많은 업데이트 보기Recent updates공시 • Oct 31Oncoinvent ASA (OB:ONCIN) completed the acquisition of BerGenBio ASA (OB:BGBIO) from Hadean Capital I AS and Hventures Capital I AB, managed by Hadean Ventures and others in a reverse merger transaction.Oncoinvent ASA (OB:ONCIN) agreed to acquire BerGenBio ASA (OB:BGBIO) from Hadean Capital I AS and Hventures Capital I AB, managed by Hadean Ventures and others in a reverse merger transaction for approximately NOK 220 million on June 30, 2025. As part of the deal, NOK 217.47 million shall be paid towards the common equity of BerGenBio ASA. The exchange ratio for the merger is 1.20268049. This is an all-share transaction, the BerGenBio shareholders will receive 25% and Oncoinvent 75% of this merged company. And technically, it's BerGenBio will be the surviving entity, but it will be then we name Oncoinvent. So Oncoinvent will be the name going forward when this is all fully completed. Øystein Soug and Tore Kvam will be appointed as the CEO and CFO of the merged entity respectively. The transaction is subject to approval by regulatory board / committee, approval of offer by acquirer shareholders, approval of offer by target shareholders and approval/consents of lenders/creditors. The expected completion of the transaction is around mid-September 2025. As of September 17, 2025 the Merger will be completed on or about 29 October 2025. ABG Sundal Collier ASA acted as financial advisor for Oncoinvent ASA. Advokatfirmaet Schjødt As acted as legal advisor for Oncoinvent ASA. DNB Carnegie acted as financial advisor for BerGenBio ASA. Advokatfirmaet Thommessen AS acted as legal advisor for BerGenBio ASA. Oncoinvent ASA (OB:ONCIN) completed the acquisition of BerGenBio ASA (OB:BGBIO) from Hadean Capital I AS and Hventures Capital I AB, managed by Hadean Ventures and others in a reverse merger transaction on October 29, 2025.공시 • Oct 30BerGenBio ASA, Annual General Meeting, May 20, 2026BerGenBio ASA, Annual General Meeting, May 20, 2026.공시 • Jul 01BerGenBio ASA (OB:BGBIO) agreed to acquire Oncoinvent ASA (OB:ONCIN) from Hadean Capital I AS and Hventures Capital I AB, managed by Hadean Ventures and others for NOK 164.2 million.BerGenBio ASA (OB:BGBIO) agreed to acquire Oncoinvent ASA (OB:ONCIN) from Hadean Capital I AS and Hventures Capital I AB, managed by Hadean Ventures and others for NOK 164.2 million on June 30, 2025. Aspart of the consideration, BerGenBio ASA will issue 117.6 million shares to Oncoinvent ASA. The exchange ratio for the merger is 1.20268049. The merged company is expected to be renamed Oncoinvent. Øystein Soug and Tore Kvam will be appointed as the CEO and CFO of the merged entity respectively. The transaction is subject to approval by regulatory board / committee, approval of offer by acquirer shareholders, approval of offer by target shareholders and approval/consents of lenders/creditors. The expected completion of the transaction is around mid-September 2025. ABG Sundal Collier ASA acted as financial advisor for Oncoinvent ASA. Advokatfirmaet Schjødt As acted as legal advisor for Oncoinvent ASA. DNB Carnegie acted as financial advisor for BerGenBio ASA. Advokatfirmaet Thommessen AS acted as legal advisor for BerGenBio ASA.공시 • Mar 26BerGenBio ASA Announces Nature Communications Publication of BGBC003 Ph2 Data in Relapsed/Refractory Acute Myeloid Leukemia PatientsBerGenBio ASA announced the publication of a peer-reviewed article entitled "Bemcentinib as Monotherapy and in Combination with Low-Dose Cytarabine in Acute Myeloid Leukemia Patients Unfit for Intensive Chemotherapy" in the journal Nature Communications. The article highlights results in 36 patients treated with a combination of BerGenBio's selective oral AXL inhibitor bemcentinib in combination with low-dose cytarabine (LDAC) chemotherapy. Overall, patients who received the combination had an overall survival of 7.8 months, substantially longer than that expected in this difficult-to-treat patient population.공시 • Feb 26BerGenBio ASA Announces Discinuation of 1L STK11M NSCLC Study and Exploration of Strategic AlternativesBerGenBio ASA announced its decision to close its BGBC016 study of bemcentinib in combination with standard of care therapy in first line (1L) non-squamous Non-Small Cell Lung Cancer (NSCLC) patients with a mutation in the STK11 gene (STK11m). In 2024, the company announced the completion of enrollment in the Ph1b portion of the study which demonstrated acceptable safety in 1L NSCLC patients regardless of STK11 mutational status, as evaluated by an independent Data Safety Monitoring Board (DSMB). Early encouraging data were seen in three STK11m patients, including one patient who experienced a complete response and who remains in response and on treatment after nearly two years. The company, in agreement with the independent DSMB, determined that these initial results warranted the continuation of the study into the Ph2a portion. In March 2024, the company initiated the Ph2a portion of the study designed to recruit 40 evaluable 1L STK11m NSCLC patients. The primary endpoint for the Ph2a was overall response rate (ORR). To determine the feasibility of obtaining near-term funding, the company performed a preliminary analysis of the responses in the 10 efficacy evaluable STK11m patients. While there was 1 response in the Ph1b the company did not observe additional responses in the Ph2a patients. Consequently, the company has decided to discontinue the BGBC016 study. The Board of Directors has now initiated an exploration of strategic alternatives. As part of this process, the board will consider a range of options for the company including, among other things, a potential sale, merger, or other strategic transaction. There can be no assurance that this exploration process will result in any transaction.공시 • Jan 07Bergenbio Asa Announces First Patient Enters into Advanced Adenocarcinoma Lung Cancer TrialBerGenBio ASA announced that the first patient has been included in a clinical trial sponsored by the Mays Cancer Center at The University of Texas Health Science Center at San Antonio (UT Health San Antonio). The study is led by Josephine A. Taverna, MD, a thoracic oncologist at the Mays Cancer Center and Associate Professor in the Division of Hematology and Oncology at UT Health San Antonio. The trial is designed to study BerGenBio's bemcentinib in combination with pacritinib, which is a JAK2 inhibitor indicated for treatment of the bone marrow disorder myelofibrosis in patients with platelet counts below 50 x 109/L. It works by blocking certain growth factors and cytokines. Pacritinib is marketed in the United States as VONJO and owned by Swedish Orphan Biovitrum AB (Sobi), a specialized international biopharmaceutical company. Bemcentinib is a first-in-class, selective, oral once-a-day inhibitor of AXL receptor tyrosine kinase, a promising therapeutic target for serious diseases. The study will include patients with lung adenocarcinoma, the most common type of lung cancer in the United States, accounting for approximately 40% of all lung cancers. The study is funded by a grant from the National Cancer Institute (NCI) of the National Institutes of Health (NIH).공시 • Dec 16BerGenBio ASA, Annual General Meeting, May 20, 2025BerGenBio ASA, Annual General Meeting, May 20, 2025.공시 • Dec 14+ 3 more updatesBerGenBio ASA to Report Q4, 2025 Results on Feb 19, 2026BerGenBio ASA announced that they will report Q4, 2025 results on Feb 19, 2026공시 • Nov 21BerGenBio ASA Appoints Olav Hellebø as CEO, Effective November 21, 2024BerGenBio ASA announced the appointment of Olav Hellebø as CEO. Mr. Hellebø will assume the position on November 21, 2024. Mr. Hellebø brings three decades of experience in the pharmaceutical and biotechnology industries. Since 2023, he has served as board director in the clinical stage immuno-oncology company Cytovation ASA, and since 2021 he has been a board director at the clinical stage biopharmaceutical company, Antev Ltd, specializing in urology and oncology treatments. Prior to this, Mr. Hellebø's experience includes the role as CEO of ReNeuron Group PLC, a UK-based clinical-stage company specializing in cell therapy for ophthalmic and neurology-related diseases, and CEO at Clavis Pharma ASA, an oncology-focused biotech company traded at the Oslo Stock Exchange. Mr. Hellebø's earlier career includes leadership roles at UCB-Celltech, Novartis UK, and at Schering-Plough (now part of Merck & Co.).공시 • Oct 11Martin Olin to Step Down from BerGenBio ASA as CEOBerGenBio ASA announced that CEO, Martin Olin will be leaving the company to pursue other opportunities. Martin will remain in his position during a transition period. The Board of Directors has initiated a succession process and will actively work with the management to support and review the business requirements.공시 • Oct 07BerGenBio ASA Announces Safety Data from Dose Escalation Phase 1b in First Line NSCLC PatientsBerGenBio ASA announced preliminary safety data from the Phase 1b portion of the BGBC016 study in first-line (1L) Non-Small Cell Lung Cancer (NSCLC) patients. The Phase 1b part of the study evaluated three escalating doses of BerGenBio's selective AXL inhibitor bemcentinib in combination with standard chemo-immunotherapy (CIT), doublet chemotherapy and pembrolizumab, Keytruda, for the 1L treatment of advanced/metastatic NSCLC patients. The primary endpoint was the assessment of the safety profile of the combination in NSCLC patients regardless of their STK11 mutational status. Key conclusions include: All three selected doses demonstrated that the triplet combination is well tolerated with no new safety signals identified, supporting the further clinical development of bemcentinib and CIT in 1L NSCLC patients. No dose-related impact on electrocardiographic changes (QTc), a known class effect of tyrosine kinase inhibitors, was reported for bemcentinib during the observation period. Pharmacokinetic analyses confirmed adequate plasma exposure of bemcentinib, achieving levels consistent with that previously observed in responders in BerGenBio's BGBC008 study of bemcentinib and pembrolizumab in second-line NSCLC patients.공시 • Dec 16BerGenBio ASA Announces Closure of EU-Solidact Bemcentinib Study Arm in Hospitalized COVID-19 PatientsBerGenBio ASA announced that the Trial Steering Committee of the EU-SolidAct has recommended to discontinue the bemcentinib study arm in the Ph2b EU-SolidAct platform study in hospitalized COVID-19 patients due to a lack of eligible patients. This recommendation is supported by BerGenBio. The regulatory sponsor of the study, Oslo University Hospital, will enact this decision. In April 2023, BerGenBio announced that the parties unanimously decided to pause the bemcentinib study arm due to a lack of eligible patients. The parties also agreed that a potential resumption of the study arm would be subject to eligible patients being available. BerGenBio will not incur any financial impact from the closure of the bemcentinib study arm.공시 • Dec 11BerGenBio ASA Announces Final Bemcentinib Phase 2 Data in AML and MDS Presented at the 2023 ASH MeetingBerGenBio ASA announced that a poster highlighting final results from a Phase 2 clinical study of its highly selective AXL inhibitor bemcentinib in patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) was presented during the 2023 American Society of Hematology (ASH) Annual Meeting being on December 9th in San Diego, CA. The data presented by Professor Sonja Loges, MD, Ph.D. of the University Medical Centre Mannheim, Heidelberg, Germany, showed that bemcentinib was well tolerated in AML and MDS patients. Durable responses were observed across all cohorts with bemcentinib as monotherapy and in combination with chemotherapy. In addition, longitudinal samples analyzed from patients enrolled in the study showed that bemcentinIB inhibited pAXL and downstream markers of activation. This large Phase 2 study included 122 patients in several cohorts of AML and MDS patients treated with bemcentinib monotherapy or in combination with two different chemotherapies.공시 • Dec 08BerGenBio ASA has completed a Follow-on Equity Offering in the amount of €240.87 million.BerGenBio ASA has completed a Follow-on Equity Offering in the amount of €240.87 million. Security Name: Shares Security Type: Common Stock Securities Offered: 10,500,000 Price\Range: €22.94 Transaction Features: Subsequent Direct Listing공시 • Nov 14+ 4 more updatesBerGenBio ASA to Report Q4, 2024 Results on Feb 19, 2025BerGenBio ASA announced that they will report Q4, 2024 results on Feb 19, 2025공시 • Jun 15BerGenBio ASA has completed a Follow-on Equity Offering in the amount of NOK 250 million.BerGenBio ASA has completed a Follow-on Equity Offering in the amount of NOK 250 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 1,750,000,000 Price\Range: NOK 0.1 Discount Per Security: NOK 0.012 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 750,000,000 Price\Range: NOK 0.1 Transaction Features: Rights Offering공시 • May 10BerGenBio ASA to Report Q1, 2023 Results on Jun 22, 2023BerGenBio ASA announced that they will report Q1, 2023 results at 12:00 PM, Central European Standard Time on Jun 22, 2023공시 • Dec 22+ 1 more updateBerGenBio ASA to Report Q4, 2023 Results on Feb 15, 2024BerGenBio ASA announced that they will report Q4, 2023 results on Feb 15, 2024주주 수익률BRRG.FUS BiotechsUS 시장7D0%-1.6%-0.8%1Yn/a34.4%27.1%전체 주주 수익률 보기수익률 대 산업: BRRG.F의 US Biotechs 산업 대비 성과를 판단하기에 데이터가 부족합니다.수익률 대 시장: BRRG.F의 US 시장 대비 성과를 판단하기에 데이터가 부족합니다.주가 변동성Is BRRG.F's price volatile compared to industry and market?BRRG.F volatilityBRRG.F Average Weekly Movementn/aBiotechs Industry Average Movement11.0%Market Average Movement7.2%10% most volatile stocks in US Market16.3%10% least volatile stocks in US Market3.2%안정적인 주가: BRRG.F는 지난 3개월 동안 US 시장에 비해 주가 변동성이 크지 않았습니다.시간에 따른 변동성: Insufficient data to determine BRRG.F의 변동성 변화를 판단할 수 없습니다.회사 소개설립직원 수CEO웹사이트200725Martin Olinwww.bergenbio.com더 보기BerGenBio ASA 기초 지표 요약BerGenBio의 순이익과 매출은 시가총액과 어떻게 비교됩니까?BRRG.F 기초 통계시가총액US$58.12m순이익 (TTM)-US$18.05m매출 (TTM)US$33.56k1,732x주가매출비율(P/S)-3.2x주가수익비율(P/E)BRRG.F는 고평가되어 있습니까?공정 가치 및 평가 분석 보기순이익 및 매출최근 실적 보고서(TTM)의 주요 수익성 지표BRRG.F 손익계산서 (TTM)매출NOK 354.00k매출원가NOK 0총이익NOK 354.00k기타 비용NOK 190.76m순이익-NOK 190.40m최근 보고된 실적Dec 31, 2023다음 실적 발표일Apr 30, 2024주당순이익(EPS)-0.071총이익률100.00%순이익률-53,785.59%부채/자본 비율0%BRRG.F의 장기 실적은 어땠습니까?과거 실적 및 비교 보기View Valuation기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2024/02/26 20:20종가2023/11/29 00:00수익2023/12/31연간 수익2023/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스BerGenBio ASA는 3명의 분석가가 다루고 있습니다. 이 중 2명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Ulrik TrattnerCarnegie Investment Bank ABGeir HolomDNB CarnegieSean ConroyEdison Investment Research
공시 • Oct 31Oncoinvent ASA (OB:ONCIN) completed the acquisition of BerGenBio ASA (OB:BGBIO) from Hadean Capital I AS and Hventures Capital I AB, managed by Hadean Ventures and others in a reverse merger transaction.Oncoinvent ASA (OB:ONCIN) agreed to acquire BerGenBio ASA (OB:BGBIO) from Hadean Capital I AS and Hventures Capital I AB, managed by Hadean Ventures and others in a reverse merger transaction for approximately NOK 220 million on June 30, 2025. As part of the deal, NOK 217.47 million shall be paid towards the common equity of BerGenBio ASA. The exchange ratio for the merger is 1.20268049. This is an all-share transaction, the BerGenBio shareholders will receive 25% and Oncoinvent 75% of this merged company. And technically, it's BerGenBio will be the surviving entity, but it will be then we name Oncoinvent. So Oncoinvent will be the name going forward when this is all fully completed. Øystein Soug and Tore Kvam will be appointed as the CEO and CFO of the merged entity respectively. The transaction is subject to approval by regulatory board / committee, approval of offer by acquirer shareholders, approval of offer by target shareholders and approval/consents of lenders/creditors. The expected completion of the transaction is around mid-September 2025. As of September 17, 2025 the Merger will be completed on or about 29 October 2025. ABG Sundal Collier ASA acted as financial advisor for Oncoinvent ASA. Advokatfirmaet Schjødt As acted as legal advisor for Oncoinvent ASA. DNB Carnegie acted as financial advisor for BerGenBio ASA. Advokatfirmaet Thommessen AS acted as legal advisor for BerGenBio ASA. Oncoinvent ASA (OB:ONCIN) completed the acquisition of BerGenBio ASA (OB:BGBIO) from Hadean Capital I AS and Hventures Capital I AB, managed by Hadean Ventures and others in a reverse merger transaction on October 29, 2025.
공시 • Oct 30BerGenBio ASA, Annual General Meeting, May 20, 2026BerGenBio ASA, Annual General Meeting, May 20, 2026.
공시 • Jul 01BerGenBio ASA (OB:BGBIO) agreed to acquire Oncoinvent ASA (OB:ONCIN) from Hadean Capital I AS and Hventures Capital I AB, managed by Hadean Ventures and others for NOK 164.2 million.BerGenBio ASA (OB:BGBIO) agreed to acquire Oncoinvent ASA (OB:ONCIN) from Hadean Capital I AS and Hventures Capital I AB, managed by Hadean Ventures and others for NOK 164.2 million on June 30, 2025. Aspart of the consideration, BerGenBio ASA will issue 117.6 million shares to Oncoinvent ASA. The exchange ratio for the merger is 1.20268049. The merged company is expected to be renamed Oncoinvent. Øystein Soug and Tore Kvam will be appointed as the CEO and CFO of the merged entity respectively. The transaction is subject to approval by regulatory board / committee, approval of offer by acquirer shareholders, approval of offer by target shareholders and approval/consents of lenders/creditors. The expected completion of the transaction is around mid-September 2025. ABG Sundal Collier ASA acted as financial advisor for Oncoinvent ASA. Advokatfirmaet Schjødt As acted as legal advisor for Oncoinvent ASA. DNB Carnegie acted as financial advisor for BerGenBio ASA. Advokatfirmaet Thommessen AS acted as legal advisor for BerGenBio ASA.
공시 • Mar 26BerGenBio ASA Announces Nature Communications Publication of BGBC003 Ph2 Data in Relapsed/Refractory Acute Myeloid Leukemia PatientsBerGenBio ASA announced the publication of a peer-reviewed article entitled "Bemcentinib as Monotherapy and in Combination with Low-Dose Cytarabine in Acute Myeloid Leukemia Patients Unfit for Intensive Chemotherapy" in the journal Nature Communications. The article highlights results in 36 patients treated with a combination of BerGenBio's selective oral AXL inhibitor bemcentinib in combination with low-dose cytarabine (LDAC) chemotherapy. Overall, patients who received the combination had an overall survival of 7.8 months, substantially longer than that expected in this difficult-to-treat patient population.
공시 • Feb 26BerGenBio ASA Announces Discinuation of 1L STK11M NSCLC Study and Exploration of Strategic AlternativesBerGenBio ASA announced its decision to close its BGBC016 study of bemcentinib in combination with standard of care therapy in first line (1L) non-squamous Non-Small Cell Lung Cancer (NSCLC) patients with a mutation in the STK11 gene (STK11m). In 2024, the company announced the completion of enrollment in the Ph1b portion of the study which demonstrated acceptable safety in 1L NSCLC patients regardless of STK11 mutational status, as evaluated by an independent Data Safety Monitoring Board (DSMB). Early encouraging data were seen in three STK11m patients, including one patient who experienced a complete response and who remains in response and on treatment after nearly two years. The company, in agreement with the independent DSMB, determined that these initial results warranted the continuation of the study into the Ph2a portion. In March 2024, the company initiated the Ph2a portion of the study designed to recruit 40 evaluable 1L STK11m NSCLC patients. The primary endpoint for the Ph2a was overall response rate (ORR). To determine the feasibility of obtaining near-term funding, the company performed a preliminary analysis of the responses in the 10 efficacy evaluable STK11m patients. While there was 1 response in the Ph1b the company did not observe additional responses in the Ph2a patients. Consequently, the company has decided to discontinue the BGBC016 study. The Board of Directors has now initiated an exploration of strategic alternatives. As part of this process, the board will consider a range of options for the company including, among other things, a potential sale, merger, or other strategic transaction. There can be no assurance that this exploration process will result in any transaction.
공시 • Jan 07Bergenbio Asa Announces First Patient Enters into Advanced Adenocarcinoma Lung Cancer TrialBerGenBio ASA announced that the first patient has been included in a clinical trial sponsored by the Mays Cancer Center at The University of Texas Health Science Center at San Antonio (UT Health San Antonio). The study is led by Josephine A. Taverna, MD, a thoracic oncologist at the Mays Cancer Center and Associate Professor in the Division of Hematology and Oncology at UT Health San Antonio. The trial is designed to study BerGenBio's bemcentinib in combination with pacritinib, which is a JAK2 inhibitor indicated for treatment of the bone marrow disorder myelofibrosis in patients with platelet counts below 50 x 109/L. It works by blocking certain growth factors and cytokines. Pacritinib is marketed in the United States as VONJO and owned by Swedish Orphan Biovitrum AB (Sobi), a specialized international biopharmaceutical company. Bemcentinib is a first-in-class, selective, oral once-a-day inhibitor of AXL receptor tyrosine kinase, a promising therapeutic target for serious diseases. The study will include patients with lung adenocarcinoma, the most common type of lung cancer in the United States, accounting for approximately 40% of all lung cancers. The study is funded by a grant from the National Cancer Institute (NCI) of the National Institutes of Health (NIH).
공시 • Oct 31Oncoinvent ASA (OB:ONCIN) completed the acquisition of BerGenBio ASA (OB:BGBIO) from Hadean Capital I AS and Hventures Capital I AB, managed by Hadean Ventures and others in a reverse merger transaction.Oncoinvent ASA (OB:ONCIN) agreed to acquire BerGenBio ASA (OB:BGBIO) from Hadean Capital I AS and Hventures Capital I AB, managed by Hadean Ventures and others in a reverse merger transaction for approximately NOK 220 million on June 30, 2025. As part of the deal, NOK 217.47 million shall be paid towards the common equity of BerGenBio ASA. The exchange ratio for the merger is 1.20268049. This is an all-share transaction, the BerGenBio shareholders will receive 25% and Oncoinvent 75% of this merged company. And technically, it's BerGenBio will be the surviving entity, but it will be then we name Oncoinvent. So Oncoinvent will be the name going forward when this is all fully completed. Øystein Soug and Tore Kvam will be appointed as the CEO and CFO of the merged entity respectively. The transaction is subject to approval by regulatory board / committee, approval of offer by acquirer shareholders, approval of offer by target shareholders and approval/consents of lenders/creditors. The expected completion of the transaction is around mid-September 2025. As of September 17, 2025 the Merger will be completed on or about 29 October 2025. ABG Sundal Collier ASA acted as financial advisor for Oncoinvent ASA. Advokatfirmaet Schjødt As acted as legal advisor for Oncoinvent ASA. DNB Carnegie acted as financial advisor for BerGenBio ASA. Advokatfirmaet Thommessen AS acted as legal advisor for BerGenBio ASA. Oncoinvent ASA (OB:ONCIN) completed the acquisition of BerGenBio ASA (OB:BGBIO) from Hadean Capital I AS and Hventures Capital I AB, managed by Hadean Ventures and others in a reverse merger transaction on October 29, 2025.
공시 • Oct 30BerGenBio ASA, Annual General Meeting, May 20, 2026BerGenBio ASA, Annual General Meeting, May 20, 2026.
공시 • Jul 01BerGenBio ASA (OB:BGBIO) agreed to acquire Oncoinvent ASA (OB:ONCIN) from Hadean Capital I AS and Hventures Capital I AB, managed by Hadean Ventures and others for NOK 164.2 million.BerGenBio ASA (OB:BGBIO) agreed to acquire Oncoinvent ASA (OB:ONCIN) from Hadean Capital I AS and Hventures Capital I AB, managed by Hadean Ventures and others for NOK 164.2 million on June 30, 2025. Aspart of the consideration, BerGenBio ASA will issue 117.6 million shares to Oncoinvent ASA. The exchange ratio for the merger is 1.20268049. The merged company is expected to be renamed Oncoinvent. Øystein Soug and Tore Kvam will be appointed as the CEO and CFO of the merged entity respectively. The transaction is subject to approval by regulatory board / committee, approval of offer by acquirer shareholders, approval of offer by target shareholders and approval/consents of lenders/creditors. The expected completion of the transaction is around mid-September 2025. ABG Sundal Collier ASA acted as financial advisor for Oncoinvent ASA. Advokatfirmaet Schjødt As acted as legal advisor for Oncoinvent ASA. DNB Carnegie acted as financial advisor for BerGenBio ASA. Advokatfirmaet Thommessen AS acted as legal advisor for BerGenBio ASA.
공시 • Mar 26BerGenBio ASA Announces Nature Communications Publication of BGBC003 Ph2 Data in Relapsed/Refractory Acute Myeloid Leukemia PatientsBerGenBio ASA announced the publication of a peer-reviewed article entitled "Bemcentinib as Monotherapy and in Combination with Low-Dose Cytarabine in Acute Myeloid Leukemia Patients Unfit for Intensive Chemotherapy" in the journal Nature Communications. The article highlights results in 36 patients treated with a combination of BerGenBio's selective oral AXL inhibitor bemcentinib in combination with low-dose cytarabine (LDAC) chemotherapy. Overall, patients who received the combination had an overall survival of 7.8 months, substantially longer than that expected in this difficult-to-treat patient population.
공시 • Feb 26BerGenBio ASA Announces Discinuation of 1L STK11M NSCLC Study and Exploration of Strategic AlternativesBerGenBio ASA announced its decision to close its BGBC016 study of bemcentinib in combination with standard of care therapy in first line (1L) non-squamous Non-Small Cell Lung Cancer (NSCLC) patients with a mutation in the STK11 gene (STK11m). In 2024, the company announced the completion of enrollment in the Ph1b portion of the study which demonstrated acceptable safety in 1L NSCLC patients regardless of STK11 mutational status, as evaluated by an independent Data Safety Monitoring Board (DSMB). Early encouraging data were seen in three STK11m patients, including one patient who experienced a complete response and who remains in response and on treatment after nearly two years. The company, in agreement with the independent DSMB, determined that these initial results warranted the continuation of the study into the Ph2a portion. In March 2024, the company initiated the Ph2a portion of the study designed to recruit 40 evaluable 1L STK11m NSCLC patients. The primary endpoint for the Ph2a was overall response rate (ORR). To determine the feasibility of obtaining near-term funding, the company performed a preliminary analysis of the responses in the 10 efficacy evaluable STK11m patients. While there was 1 response in the Ph1b the company did not observe additional responses in the Ph2a patients. Consequently, the company has decided to discontinue the BGBC016 study. The Board of Directors has now initiated an exploration of strategic alternatives. As part of this process, the board will consider a range of options for the company including, among other things, a potential sale, merger, or other strategic transaction. There can be no assurance that this exploration process will result in any transaction.
공시 • Jan 07Bergenbio Asa Announces First Patient Enters into Advanced Adenocarcinoma Lung Cancer TrialBerGenBio ASA announced that the first patient has been included in a clinical trial sponsored by the Mays Cancer Center at The University of Texas Health Science Center at San Antonio (UT Health San Antonio). The study is led by Josephine A. Taverna, MD, a thoracic oncologist at the Mays Cancer Center and Associate Professor in the Division of Hematology and Oncology at UT Health San Antonio. The trial is designed to study BerGenBio's bemcentinib in combination with pacritinib, which is a JAK2 inhibitor indicated for treatment of the bone marrow disorder myelofibrosis in patients with platelet counts below 50 x 109/L. It works by blocking certain growth factors and cytokines. Pacritinib is marketed in the United States as VONJO and owned by Swedish Orphan Biovitrum AB (Sobi), a specialized international biopharmaceutical company. Bemcentinib is a first-in-class, selective, oral once-a-day inhibitor of AXL receptor tyrosine kinase, a promising therapeutic target for serious diseases. The study will include patients with lung adenocarcinoma, the most common type of lung cancer in the United States, accounting for approximately 40% of all lung cancers. The study is funded by a grant from the National Cancer Institute (NCI) of the National Institutes of Health (NIH).
공시 • Dec 16BerGenBio ASA, Annual General Meeting, May 20, 2025BerGenBio ASA, Annual General Meeting, May 20, 2025.
공시 • Dec 14+ 3 more updatesBerGenBio ASA to Report Q4, 2025 Results on Feb 19, 2026BerGenBio ASA announced that they will report Q4, 2025 results on Feb 19, 2026
공시 • Nov 21BerGenBio ASA Appoints Olav Hellebø as CEO, Effective November 21, 2024BerGenBio ASA announced the appointment of Olav Hellebø as CEO. Mr. Hellebø will assume the position on November 21, 2024. Mr. Hellebø brings three decades of experience in the pharmaceutical and biotechnology industries. Since 2023, he has served as board director in the clinical stage immuno-oncology company Cytovation ASA, and since 2021 he has been a board director at the clinical stage biopharmaceutical company, Antev Ltd, specializing in urology and oncology treatments. Prior to this, Mr. Hellebø's experience includes the role as CEO of ReNeuron Group PLC, a UK-based clinical-stage company specializing in cell therapy for ophthalmic and neurology-related diseases, and CEO at Clavis Pharma ASA, an oncology-focused biotech company traded at the Oslo Stock Exchange. Mr. Hellebø's earlier career includes leadership roles at UCB-Celltech, Novartis UK, and at Schering-Plough (now part of Merck & Co.).
공시 • Oct 11Martin Olin to Step Down from BerGenBio ASA as CEOBerGenBio ASA announced that CEO, Martin Olin will be leaving the company to pursue other opportunities. Martin will remain in his position during a transition period. The Board of Directors has initiated a succession process and will actively work with the management to support and review the business requirements.
공시 • Oct 07BerGenBio ASA Announces Safety Data from Dose Escalation Phase 1b in First Line NSCLC PatientsBerGenBio ASA announced preliminary safety data from the Phase 1b portion of the BGBC016 study in first-line (1L) Non-Small Cell Lung Cancer (NSCLC) patients. The Phase 1b part of the study evaluated three escalating doses of BerGenBio's selective AXL inhibitor bemcentinib in combination with standard chemo-immunotherapy (CIT), doublet chemotherapy and pembrolizumab, Keytruda, for the 1L treatment of advanced/metastatic NSCLC patients. The primary endpoint was the assessment of the safety profile of the combination in NSCLC patients regardless of their STK11 mutational status. Key conclusions include: All three selected doses demonstrated that the triplet combination is well tolerated with no new safety signals identified, supporting the further clinical development of bemcentinib and CIT in 1L NSCLC patients. No dose-related impact on electrocardiographic changes (QTc), a known class effect of tyrosine kinase inhibitors, was reported for bemcentinib during the observation period. Pharmacokinetic analyses confirmed adequate plasma exposure of bemcentinib, achieving levels consistent with that previously observed in responders in BerGenBio's BGBC008 study of bemcentinib and pembrolizumab in second-line NSCLC patients.
공시 • Dec 16BerGenBio ASA Announces Closure of EU-Solidact Bemcentinib Study Arm in Hospitalized COVID-19 PatientsBerGenBio ASA announced that the Trial Steering Committee of the EU-SolidAct has recommended to discontinue the bemcentinib study arm in the Ph2b EU-SolidAct platform study in hospitalized COVID-19 patients due to a lack of eligible patients. This recommendation is supported by BerGenBio. The regulatory sponsor of the study, Oslo University Hospital, will enact this decision. In April 2023, BerGenBio announced that the parties unanimously decided to pause the bemcentinib study arm due to a lack of eligible patients. The parties also agreed that a potential resumption of the study arm would be subject to eligible patients being available. BerGenBio will not incur any financial impact from the closure of the bemcentinib study arm.
공시 • Dec 11BerGenBio ASA Announces Final Bemcentinib Phase 2 Data in AML and MDS Presented at the 2023 ASH MeetingBerGenBio ASA announced that a poster highlighting final results from a Phase 2 clinical study of its highly selective AXL inhibitor bemcentinib in patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) was presented during the 2023 American Society of Hematology (ASH) Annual Meeting being on December 9th in San Diego, CA. The data presented by Professor Sonja Loges, MD, Ph.D. of the University Medical Centre Mannheim, Heidelberg, Germany, showed that bemcentinib was well tolerated in AML and MDS patients. Durable responses were observed across all cohorts with bemcentinib as monotherapy and in combination with chemotherapy. In addition, longitudinal samples analyzed from patients enrolled in the study showed that bemcentinIB inhibited pAXL and downstream markers of activation. This large Phase 2 study included 122 patients in several cohorts of AML and MDS patients treated with bemcentinib monotherapy or in combination with two different chemotherapies.
공시 • Dec 08BerGenBio ASA has completed a Follow-on Equity Offering in the amount of €240.87 million.BerGenBio ASA has completed a Follow-on Equity Offering in the amount of €240.87 million. Security Name: Shares Security Type: Common Stock Securities Offered: 10,500,000 Price\Range: €22.94 Transaction Features: Subsequent Direct Listing
공시 • Nov 14+ 4 more updatesBerGenBio ASA to Report Q4, 2024 Results on Feb 19, 2025BerGenBio ASA announced that they will report Q4, 2024 results on Feb 19, 2025
공시 • Jun 15BerGenBio ASA has completed a Follow-on Equity Offering in the amount of NOK 250 million.BerGenBio ASA has completed a Follow-on Equity Offering in the amount of NOK 250 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 1,750,000,000 Price\Range: NOK 0.1 Discount Per Security: NOK 0.012 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 750,000,000 Price\Range: NOK 0.1 Transaction Features: Rights Offering
공시 • May 10BerGenBio ASA to Report Q1, 2023 Results on Jun 22, 2023BerGenBio ASA announced that they will report Q1, 2023 results at 12:00 PM, Central European Standard Time on Jun 22, 2023
공시 • Dec 22+ 1 more updateBerGenBio ASA to Report Q4, 2023 Results on Feb 15, 2024BerGenBio ASA announced that they will report Q4, 2023 results on Feb 15, 2024
